Free Trial

This company has been marked as potentially delisted and may not be actively trading.

IMARA (IMRA) Competitors

IMARA logo

IMRA vs. MOR, GMTX, CALT, ZYME, SBTX, MBX, AVTE, NLTX, BIOA, and ELYM

Should you be buying IMARA stock or one of its competitors? The main competitors of IMARA include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), and Eliem Therapeutics (ELYM).

IMARA vs. Its Competitors

IMARA (NASDAQ:IMRA) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

49.3% of IMARA shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 37.3% of IMARA shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

IMARA has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMARAN/AN/A$1.49M$0.05735.40
MorphoSys$238.28M11.99-$205.35M-$3.48-5.45

IMARA has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

In the previous week, IMARA had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for IMARA and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat IMARA's score of 0.00 indicating that MorphoSys is being referred to more favorably in the news media.

Company Overall Sentiment
IMARA Neutral
MorphoSys Neutral

IMARA has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. IMARA's return on equity of 2.12% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
IMARAN/A 2.12% 2.00%
MorphoSys -226.79%-694.31%-22.55%

Summary

IMARA beats MorphoSys on 9 of the 12 factors compared between the two stocks.

Get IMARA News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMRA vs. The Competition

MetricIMARAPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$964.62M$927.71M$5.79B$10.15B
Dividend YieldN/A4.84%5.69%4.61%
P/E Ratio735.551.1574.5925.92
Price / SalesN/A27.04449.5483.33
Price / Cash75.2419.5637.0859.91
Price / Book10.696.6912.156.29
Net Income$1.49M-$4.50M$3.28B$270.85M

IMARA Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMRA
IMARA
N/A$36.77
-0.5%
N/AN/A$964.62MN/A735.5541Insider Trade
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
GMTX
Gemini Therapeutics
N/A$61.91
+1.9%
N/A+21.0%$2.68BN/A-61.9130High Trading Volume
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180News Coverage
ZYME
Zymeworks
2.3851 of 5 stars
$15.23
+0.3%
$21.43
+40.7%
+34.9%$1.14B$122.87M-10.15460Positive News
SBTX
Silverback Therapeutics
N/A$10.70
+6.3%
N/A-8.8%$385.82MN/A-4.4283News Coverage
High Trading Volume
MBX
MBX Biosciences
2.8142 of 5 stars
$11.42
+4.8%
$37.63
+229.5%
N/A$366.18MN/A-2.5236Positive News
AVTE
Aerovate Therapeutics
N/A$7.48
-3.7%
N/A-88.7%$216.81MN/A-2.5020Positive News
High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$19.45
-2.5%
N/A-52.7%$182.79MN/A-6.2590High Trading Volume
BIOA
BioAge Labs
0.1992 of 5 stars
$4.98
-2.2%
N/AN/A$182.48MN/A0.00N/APositive News
ELYM
Eliem Therapeutics
N/A$2.47
+3.3%
N/A-69.8%$152.03MN/A-4.669Gap Up

Related Companies and Tools


This page (NASDAQ:IMRA) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners